Zoladex
(goserelin acetate)Phase 3Small molecule
AstraZenecaGoserelin acetate is used to treat advanced prostate cancer in men and breast cancer in women, and it can also be used to manage endometriosis and uterine fibroids. It works by reducing hormone levels in the body that fuel these conditions.[1] Zoladex is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]
Zoladex is one of 281 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 3.
10
Indications
80
Total Trials
13
Active Trials
280
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zoladex
AstraZenecaPhase 3
Tykerb
GSKPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
MS Contin
Merck & Co.Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer37 trials
Show 34 more trials
Management of Castration-Resistant Prostate Cancer with Oligometastases
Active, not recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2/3·NCT02685397·102 enrolled
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Unknown status·—·Phase 2·NCT00348998·18 enrolled
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Recruiting·—·Phase 2·NCT04734730·70 enrolled
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00021450·819 enrolled
Breast Cancer22 trials
Show 19 more trials
Metastatic Prostate Cancer7 trials
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT03361735·25 enrolled
Show 4 more trials
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT00544830·29 enrolled
Prostate Adenocarcinoma2 trials
11 more indications
Fallopian Tube1 trial
ESS1 trial
Androgen Deprivation Therapy1 trial
Radiotherapy1 trial
Metabolic Syndrome1 trial
Insulin Sensitivity in Men With the Metabolic Syndrome
Suspended·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00433173·72 enrolled
Bone1 trial
BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH
Completed·—··NCT04203212·41 enrolled
Biochemical Recurrence1 trial
Salivary Gland Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for goserelin acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Gonadotropin-Releasing Hormone Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company